Neuron23

South San Francisco, California, USA · ≈42 employees · neuron23.com

Neuron23 is a developer of drugs intended to treat Parkinson's disease and Alzheimer's disease. The company was founded in 2018 and is based in San Francisco, California, United States.

Biotechnology Healthcare

Funding0

Every round, secondary, debt facility or acquisition involving Neuron23 that Lounge tracks, newest first.

No rounds recorded yet.

Paid members see the full deals desk — every AI round and exit, filterable by type, sector and country, with investors and reported ARR, plus CSV exports. Developer membership is $9/mo.

See plans →Log in

Neuron23

Funding0

Key numbers

Also on Lounge

Similar companies